热门资讯> 正文
Kodiak Sciences强调1b阶段结果，KSI-101可快速干燥视网膜并具有临床意义的视力改善
2025-09-15 19:13
- Kodiak Sciences(KOD) 0
- Kadem Sustainable Impact Corp Ordinary Shares - Class A(KSI) 0
- HEALTHPEAK PROPERTIES(PEAK) 0
- Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain)
- A single dose of KSI-101 resulted in the majority of patients achieving resolution of intra-retinal and sub-retinal fluid and over 90% of patients achieved retinal dryness by Week 8
- The Phase 3 PEAK and PINNACLE studies of KSI-101 are actively enrolling, testing the top two dose levels (5 mg and 10 mg) in patients with MESI
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
